NOVN - NOVN STOCK NEWS

Novan reported a significant 37% increase in Rhofade prescriptions for the third quarter year-to-date. The company is advancing towards a New Drug Application (NDA) submission for berdazimer gel, anticipated by year-end 2022. Financial results show total revenue of $5.1 million for Q3 2022, up from $0.7 million in Q3 2021, while net loss narrowed to $6.0 million. Total cash on hand stood at $14.9 million. Their recent debt extinguishment will allow more cash for product development and commercialization efforts.

Novan, Inc. (Nasdaq: NOVN) will report its Q3 2022 financial results on November 14, 2022, at 8:30 a.m. ET. CEO Paula Brown Stafford will lead a conference call to discuss these results. The call will be accessible to investors and interested participants through a dedicated phone line and live webcast, which will also be archived for 90 days. Novan focuses on developing innovative therapies for skin diseases, including its lead product candidate, SB206 (berdazimer gel), for viral skin infections. The recent acquisition of EPI Health enhances Novan's commercial infrastructure.

Novan and partners presented positive data on PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference, showing its effectiveness in enhancing the delivery of Calcipotriene and Betamethasone Dipropionate in WYNZORA® Cream. The technology allows for stable co-existence of these ingredients in an aqueous cream, leading to higher diffusion rates compared to traditional formulations. Study results indicated significant improvements in drug delivery, potentially explaining the efficacy noted in previous Phase 3 studies. WYNZORA® Cream is now marketed in the U.S. to treat plaque psoriasis.

Novan, Inc. (Nasdaq: NOVN) announced that eight abstracts have been accepted for poster presentation at the 42^nd Annual Fall Clinical Dermatology Conference in Las Vegas, NV, from October 20-23, 2022. The presentations will focus on topics such as the efficacy of berdazimer gel for molluscum contagiosum and improving psoriasis treatment adherence. Notably, berdazimer gel, a new topical agent in Phase 3 development, is positioned as a potential first-in-class treatment. Novan aims to address unmet medical needs with a robust development pipeline following the recent acquisition of EPI Health.

Novan, Inc. (NASDAQ: NOVN) announced a new analysis of its WYNZORA® Cream, showing its effectiveness for skin of color patients with plaque psoriasis. This analysis, presented at the Skin of Color Update 2022 Conference, demonstrated that 37.4% of patients with Fitzpatrick skin types IV-VI achieved significant improvement after 8 weeks, similar to the overall study population. Notably, no cases of hypopigmentation were reported. This data supports the role of WYNZORA Cream in providing treatment options for underrepresented populations.

Novan, Inc. (Nasdaq: NOVN) reported total revenue of $6.2 million for Q2 2022, a significant increase from $0.7 million in Q2 2021. The company's net product revenues reached $5.8 million driven by a 28% year-to-date prescription growth. Novan remains on track to submit a New Drug Application (NDA) for berdazimer gel, targeting viral skin infections, by Q4 2022. The company ended Q2 with $37.3 million in cash and executed a direct offering of $15 million in June 2022.

Novan, Inc. (Nasdaq: NOVN) will report its Q2 2022 financial results on August 11, 2022, at 8:30 a.m. ET. CEO Paula Brown Stafford will lead a conference call and live audio webcast to discuss the operational and financial outcomes. The call will be accessible via phone or through the company's website. Novan focuses on developing innovative dermatological therapies, including SB206, a treatment for viral skin infections, and has recently acquired EPI Health to enhance its commercial capabilities.

Novan, Inc. (Nasdaq: NOVN) has reached an agreement with Evening Post Group to terminate its secured promissory note, saving $11.1 million in principal and future interest payments. The $10.0 million payment fully satisfies Novan's only outstanding debt, which was secured by EPI Health assets. With the termination of this debt, Novan can now explore broader financing options without liens on its commercial operations. This strategic move is expected to enhance shareholder value and operational flexibility.